Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

December 31, 2016

Conditions
Insulin ResistanceChronic Heart Failure
Interventions
DRUG

Metformini hydrochloridum (Siofor 1000 tbl, Berlin)

"Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"

DRUG

placebo

Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.

Trial Locations (1)

Unknown

Diabetes Center, Institute of Clinical and Experimental Medicine, Prague

All Listed Sponsors
lead

Institute for Clinical and Experimental Medicine

OTHER_GOV

NCT01690091 - Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes | Biotech Hunter | Biotech Hunter